Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ciclesonide -- a new inhaled corticosteroid].

D Ukena1

  • 1Klinik für Pneumologie, Klinikum Bremen-Ost. dieter.ukena@klinikum-bremen-ost.de

Pneumologie (Stuttgart, Germany)
|October 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Drug-induced pulmonary diseases].

Der Pneumologe·2020
Same author

[Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Der Pathologe·2018
Same author

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

[Management of Lung Abscess].

Zentralblatt fur Chirurgie·2015
Same author

[Quality of Care in Certified Lung Cancer Centers].

Pneumologie (Stuttgart, Germany)·2015

Ciclesonide, an inhaled corticosteroid, is activated in the lungs, offering a prolonged effect with reduced systemic interactions and local side effects. This novel drug demonstrates an improved therapeutic index, positioning it as a new generation of inhaled corticosteroids.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Context:

  • Inhaled corticosteroids (ICS) are mainstays in managing respiratory diseases.
  • Existing ICS therapies can have systemic and local side effects.
  • Novel drug delivery and activation mechanisms are sought to improve ICS efficacy and safety.

Purpose:

  • To introduce ciclesonide, a novel inhaled corticosteroid (ICS).
  • To describe its unique on-site activation mechanism in the lungs.
  • To evaluate its efficacy, safety, and therapeutic index compared to other ICS.

Summary:

  • Ciclesonide is an inactive prodrug delivered via hydrofluoroalkane metered-dose inhaler, achieving 50-60% lung deposition.
  • In the lungs, it undergoes on-site activation to desisobutyryl-ciclesonide (des-CIC), forming a local depot for prolonged action and once-daily dosing.

Related Experiment Videos

  • High protein binding and rapid clearance minimize systemic interactions; high doses do not suppress adrenal function.
  • Lack of oropharyngeal activation results in local adverse effect rates comparable to placebo.

    • Impact:

    • Ciclesonide exhibits an improved therapeutic index due to targeted activation and reduced systemic exposure.
    • It represents a potential prototype for a new generation of inhaled corticosteroids with enhanced safety and efficacy.
    • Its favorable profile may lead to improved patient adherence and outcomes in managing respiratory conditions.